Table 1.
Association of PIK3CA mutations and amplification with clinicopathologic variables
| Variable | PIK3CA mutations (n = 113) | PIK3CA amplification (n = 131) | ||||
|---|---|---|---|---|---|---|
| Yes | No | P | Yes | No | P | |
| No.of patients | 8 | 105 | 88 | 43 | ||
| Gender | ||||||
| Male | 5 | 82 | 0.57 | 68 | 34 | 0.82 |
| Female | 3 | 23 | 20 | 9 | ||
| Age, years | ||||||
| Mean | 55.5 | 59.1 | 0.47 | 58.6 | 61.4 | 0.25 |
| SD | 19.8 | 12.7 | 13.3 | 12.1 | ||
| Tumor localization | ||||||
| gastric cardia | 0 | 26 | 0.98 | 23 | 12 | 0.66 |
| gastric body | 5 | 24 | 22 | 12 | ||
| gastric antrum | 3 | 55 | 43 | 19 | ||
| Tumor size (cm3) | ||||||
| ≤ 3 | 3 | 35 | 0.68 | 29 | 14 | 0.88 |
| 3-5 | 3 | 35 | 32 | 15 | ||
| > 5 | 2 | 35 | 27 | 14 | ||
| Differentiation | ||||||
| well/moderate | 1 | 44 | 0.21 | 33 | 23 | 0.08 |
| poor/undifferentiation | 7 | 61 | 55 | 20 | ||
| Tumor invasion | ||||||
| T1 | 2 | 14 | 0.96 | 9 | 5 | 0.59 |
| T2 | 0 | 17 | 15 | 8 | ||
| T3 | 6 | 72 | 62 | 30 | ||
| T4 | 0 | 2 | 2 | 0 | ||
| TNM stage | ||||||
| I | 2 | 27 | 0.91 | 20 | 10 | 0.86 |
| II | 1 | 14 | 15 | 6 | ||
| III | 5 | 58 | 49 | 25 | ||
| IV | 0 | 6 | 4 | 2 | ||
| Residual tumor | ||||||
| Yes | 1 | 12 | 1.00 | 12 | 2 | 0.10 |
| No | 7 | 93 | 76 | 41 | ||
| Lymph node metastasis (LNM) | ||||||
| Yes | 5 | 65 | 1.00 | 57 | 24 | 0.32 |
| No | 3 | 40 | 31 | 19 | ||
| No. of LNM | ||||||
| N0 | 3 | 40 | 0.63 | 31 | 19 | 0.20 |
| N1 (1-6) | 4 | 36 | 32 | 16 | ||
| N2 (7-15) | 1 | 23 | 20 | 7 | ||
| N3 (≥ 16) | 0 | 6 | 5 | 1 | ||
| Survival status | ||||||
| Dead | 3 | 53 | 0.73 | 51 | 15 | 0.01* |
| Alive | 5 | 52 | 37 | 28 | ||
* Significant at P < 0.05